EHA 2024 | Promising treatment strategies being explored in hairy cell leukemia
Enrico Tiacci, MD, University of Perugia, Perugia, Italy, highlights some treatment strategies being explored in patients with hairy cell leukemia (HCL). In the frontline setting, combining a BRAF inhibitor and anti-CD20 antibody, for example, vemurafenib with rituximab, may provide a chemotherapy-free alternative for frail or elderly patients or those at high risk of infection. In the relapsed/refractory (R/R) setting, agents and therapeutic approaches that have shown activity in other hematological malignancies should be trialed in the future. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kite/Gilead, Deciphera, Innate Pharma, Roche.
